p53 protein expression in cutaneous T-cell lymphomas
Corresponding Author
A. F. LAURITZEN
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Anne F. Lauritzen, Department of Pathology, Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.Search for more papers by this authorG. L. VEJLSGAARD
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorK. HOU-JENSEN
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorE. RALFKIAER
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
A. F. LAURITZEN
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Anne F. Lauritzen, Department of Pathology, Frederiksberg Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.Search for more papers by this authorG. L. VEJLSGAARD
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorK. HOU-JENSEN
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorE. RALFKIAER
Department of Pathology, Herlev Hospital, University of Copenhagen, Denmark; Departments of Dermatology and Pathology, Rigshospitalet, University of Copenhagen, Denmark
Search for more papers by this authorSummary
p53 is an oncosuppressor gene located on chromosome 17p. Point mutations of the p53 gene are seen frequently in human malignancies, and are closely associated with malignant transformation under in vitro conditions. Mutated p53 protein shows a slow cell turnover rate, and accumulates in cells at the nuclear and/or cytoplasmic level. As a result, mutated p53 protein can be detected more readily by immunohistology than the wild-type protein. In this study, we used a monoclonal anti-p53 antibody (clone D07) to examine the expression of p53 protein in 25 cutaneous T-cell lymphomas (CTCL) of low- and high-grade malignancy, i.e. mycosis fungoides (n = 6), Sézary's syndrome (n = 2), and large cell lymphomas of pleomorphic (n = 14) or anaplastic (n= 3) subtype. The results showed that easily detectable p53 protein was present in many of the neoplastic cells in half of the high-grade lymphomas. In contrast, in the low-grade lymphomas no, or only very few, p53-positive neoplastic cells could be detected. These findings suggest that molecular and/or genetic alterations of p53 may be implicated in the pathogenesis of high-grade CTCL, but are unlikely to be of critical importance in low-grade CTCL.
References
- 1 Linzer DIH, Levine AJ. Characterization of a 53 K-Dalton cellular SV-40 tumor antigen present in SV-40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52.
- 2 Lane DP, Crawford LV. T-antigen is bound to host protein in SV40 transformed cells. Nature 1979; 278: 261–3.
- 3 Lane DP, Benchimal S. P53: oncogene or antioncogene? Genes Dev 1990; 4: 1–8.
- 4 Oren M. The p53 cellular tumour antigen: gene structure, expression and protein properties. Biochim Biophys Acta 1985; 823: 67–78.
- 5 Yonish-Rouach E, Resnitzky D, Lotem J et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345–6.
- 6 Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092–6.
- 7 Bartek J, Bartkova B, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699–703.
- 8 Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219–22.
- 9 Gaidano G, Ballerini, P. Gong JZ et al. P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukaemia. Proc Natl Acad Sci USA 1991; 88: 5413–17.
- 10 Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233–7.
- 11 Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumour antigen, p53. Mol Cell Biol 1983; 3: 2143–50.
- 12 Cattoretti G, Rilke F, Andreola S et al. P53 expression in breast cancer. Int J Cancer 1988; 41: 178–83.
- 13 Cesarmann E, Chadburn A, Inghirami G et al. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205–16.
- 14 Rivas CI, Wisnievsky D, Strife A et al. Constitutive expression of p53 protein in enriched normal human marrow blast cell population. Blood 1992; 79: 1982–6.
- 15 Tadini G, Cerri A, Crosti L et al. P53 and oncogenes expression in psoriasis. Acta Derm Venereal Suppl (Stockh) 1989; 146: 33–5.
- 16 Said JW, Barrera R, Shintaku IP et al. Immunohistochemical analysis of p53 expression in malignant lymphoma. Am J Pathol 1992; 141: 1343–8.
- 17 Mori N, Wada M, Yokota J et al. Mutations of the p53 tumour suppressor gene in haematologic neoplasms. Br J Haematol 1992; 81: 235–40.
- 18 Lauritzen AF, Hou-Jensen K, Ralfkiaer E. P53 protein expression in Hodgkin's disease. APMIS 1993; 101: 689–94.
- 19 Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with mutations in anaplastic large cell lymphoma. Am J Pathol 1993; 143: 845–56.
- 20 Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Postthymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994; 144: 573–84.
- 21 Ichikawa A, Hotta T, Takagi N et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992; 79: 2701–7.
- 22 Villuendas R, Piris PA, Orradre JL et al. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992; 166: 235–41.
- 23 Pezzella F, Morrison H, Jones M et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphomas. Histopathology 1993; 22: 39–44.
- 24 Ro YS, Cooper PN, Lee AG et al. P53 protein expression in benign and malignant skin tumours. Br J Dermatol 1993; 128: 237–41.
- 25 Ralfkiaer E, Wantzin GL, Mason DY et al. Phenotypic characterization of lymphocyte subsets in mycosis fungoides. Am J Clln Pathol 1985; 84: 610–19.
- 26
Stansfeld AG,
Diebold J,
Kapanci Y
et al.
Updated Kiel classification for lymphomas.
Lancet
1988; i: 292–3.
10.1016/S0140-6736(88)90367-4 Google Scholar
- 27
Shi S-R,
Key ME,
Kalra KR.
Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for irnmuno-histochemical staining based on microwave oven heating of tissue sections.
J Histochem Cytochem
1991; 29: 741–8.
10.1177/39.6.1709656 Google Scholar
- 28 Isobe M, Emanuel BS, Givol D et al. Localisation of gene for human p53 tumour antigen to band 17pl3. Nature 1986; 320: 84–5.
- 29 Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1093–93.
- 30 Hinds PW, Finlay CA, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739–46.
- 31 Finlay CA, Hinds PW, Tan TH et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1989; 8: 531–9.
- 32 Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992; 151: 237–44.
- 33 Luka J, Jornwall H, Klein G. Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000 Dalton subunit. J Virol 1980; 35: 592–602.
- 34 Kanavaros P, Jiwa MM, De Bruin PC et al. High incidence of EBV genome in CD-30 positive non-Hodgkin's lymphomas. J Pathol 1992; 168: 307–15.
- 35 Wu X, Boyle JH, Olson DC, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126–32.
- 36 Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry?—Revisitedl J Pathol 1994; 172: 1–4.